Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.31 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.30 |
| ▸ | PPID | Q08752 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4311206 | 1.00 | CPA1 (0.54) | CPA1ALDH1A1KDM4EPOLBKMT2A | |
| SCHEMBL5163506 | 0.92 | CPA1 (0.50) | CPA1ALDH1A1KMT2ATP53SMN1; SMN2 | |
| SCHEMBL1427009 | 0.92 | CPA1 (0.50) | CPA1ALDH1A1KMT2ATP53SMN1; SMN2 | |
| SCHEMBL18191192 | 0.88 | CPA1 (0.46) | CPA1ALDH1A1POLBTP53SMN1; SMN2 | |
| SCHEMBL18191197 | 0.88 | CPA1 (0.46) | CPA1ALDH1A1POLBTP53SMN1; SMN2 | |
| SCHEMBL5245266 | 0.86 | CPA1 (0.51) | CPA1ALDH1A1SMN1; SMN2 | |
| SCHEMBL1409156 | 0.85 | CPA1 (0.61) | CPA1ALDH1A1KDM4EPOLBKMT2A | |
| SCHEMBL6855469 | 0.83 | CPA1 (0.50) | CPA1ALDH1A1PPID | |
| SCHEMBL4305803 | 0.79 | CPA1 (0.37) | CPA1ALDH1A1 | |
| SCHEMBL4305805 | 0.79 | CPA1 (0.37) | CPA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1640361-B9 | ASYMMETRIC UREA COMPOUNDS AND PROCESS FOR PRODUCING ASYMMETRIC COMPOUNDS BY ASYMMETRIC CONJUGATE ADDITION REACTION USING THE SAME AS CATALYST | SUMITOMO CHEMICAL CO (JP) | 2015-11-04 | — | — | EP | disclosed |
| EP-1640361-B1 | ASYMMETRIC UREA COMPOUNDS AND PROCESS FOR PRODUCING ASYMMETRIC COMPOUNDS BY ASYMMETRIC CONJUGATE ADDITION REACTION USING THE SAME AS CATALYST | SUMITOMO CHEMICAL CO (JP) | 2015-05-27 | — | — | EP | disclosed |
| US-7632970-B2 | Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-12-15 | — | — | US | disclosed |
| US-20060161006-A1 | Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1640361-A2 | ASYMMETRIC UREA COMPOUND AND PROCESS FOR PRODUCING ASYMMETRIC COMPOUND BY ASYMMETRIC CONJUGATE ADDITION REACTION WITH THE SAME AS CATALYST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060161006-A1 | Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst | RAD18, UTP18, UBE2G2 | CPA1 3471/4885ALDH1A1 2730/4885KDM4E 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.